Aegerion Pharmaceuticals Observes Rare Disease Day

Aegerion Pharmaceuticals Observes Rare Disease Day

Company Joins NORD, EURORDIS, CORD and Others Worldwide in Supporting
Awareness of Rare Diseases

CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, announced today its alliance with the National
Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS) and
Canadian Organization of Rare Disorders (CORD) in observance of the annual
Rare Disease Day.

"We are dedicated to creating awareness about rare diseases and to fostering
development of new treatments," said Marc D. Beer, Chief Executive Officer of
Aegerion. "Rare Disease Day is an important opportunity to support advocacy
groups for rare diseases, including The FH Foundation, and to acknowledge our
peers in the orphan drug space whose goals are aligned to treat patients with
rare diseases. We are particularly focused on supporting people with
homozygous familial hypercholesterolemia (HoFH), and are motivated every day
by our commitment to the patients."

In the United States, a rare disease is defined as one that affects fewer than
200,000 persons. According to the National Institutes of Health (NIH), there
are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare
Disease Day was established by EURORDIS and was first observed in Europe in
2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S.
For more information about Rare Disease Day, visit

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating, often fatal, rare diseases.For more information
about the company, please visit

The Aegerion Pharmaceuticals, Inc. logo is available at

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations

Aegerion Pharmaceuticals, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.